Table 2.
Comparison of the main thyTreg characteristics between Research and GMP manufacturing protocol.
| Characteristic | GMP thyTreg (n=4) | ThyTreg (n=16) |
|---|---|---|
| Donor age (mo) | 8.23 ± 6,65 | 7.50 ± 3.32 |
| Thymocytes/g (x 109) | 1.16 ± 0.26 | 1.57 ± 0.17 |
| thyTreg D0 (per 109 thymocytes) | 5.91 ± 1.42 | 6.69 ± 0.52 |
| thyTreg D7 (per 109 thymocytes) | 54.24 ± 16.83 | 51.79 ± 13.17 |
| thyTreg D7 phenotype | ||
| % of Viability | 96.58 ± 0.71 | 92.41 ± 1.02 |
| % of Purity (CD25+FoxP3+) | 83.65 ± 4.87 | 95.20 ± 0.74 |
| % of CD4+SP | 62.81 ± 2.70 | 67.73 ± 2.30 |
| % of CD4+CD8+DP | 28.43 ± 2.59 | 25.49 ± 2.26 |
| % of CTLA-4+ | 73.71 ± 1.55 | 91.68 ± 1.53 |
| % of CD39+ | 9.64 ± 2.68 | 20.39 ± 3.00 |
| % of HLA-DR+ | 22.76 ± 4.00 | 32.92 ± 3.58 |
| IL10 secretion (pg/ml) | 560.33 ± 137.56 | 188.03 ± 36.04 |
| % of Inhibition of T CD4 proliferation (1:1) | 71.48 ± 2.52 | 81.24 ± 2.31 |
| % of Inhibition of T CD8 proliferation (1:1) | 66.96 ± 7.16 | 80.52 ± 2.54 |
| TSDR demethylation (in males)* | 68.08 ± 9.15 | 89.03 ± 2.57 |
*Demethylation data corresponds to n=4 for GMP thyTreg and n=2 for research thyTreg. Data are mean ± SEM.